Loading...
Options for treating patients with type 2 diabetes continue to grow. In this systematic review and meta-analysis of 204 studies, researchers evaluated the comparative effectiveness and safety of available agents.
Eighty-one percent of included studies were randomized controlled trials (RCTs). Moderate-strength evidence showed that metformin monotherapy was associated with lower long-term (≥2 years) cardiovascular-related mortality than was sulfonylurea monotherapy (relative risk, 0.65 in RCTs), whereas evidence was insufficient or of low strength for defining differences in all-cause mortality and macrovascular or microvascular outcomes. In the short term, most medications lowered glycosylated hemoglobin levels by similar amounts; however, d…